Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Nov;30(6):548-553.
doi: 10.1097/BOR.0000000000000550.

An update on autoantibodies in scleroderma

Christopher A Mecoli  1 , Livia Casciola-Rosen
Affiliations
Review

An update on autoantibodies in scleroderma

Christopher A Mecoli et al. Curr Opin Rheumatol. 2018 Nov.

Abstract

Purpose of review: New research continues to provide important insights into the utility of antibody specificities. This review provides an update of recent findings, and the important insights they provide into disease mechanism.

Recent findings: A growing number of autoantibodies have been discovered in scleroderma patients with unique clinical associations. A subgroup of these antibodies may have functional consequences and contribute to disease pathogenesis, driving the vascular and fibrotic phenotype. Recent research into the relationship between malignancy and scleroderma onset provides important new insights into disease mechanism, and highlights the utility of autoantibodies as unique research probes.

Summary: Continued advances in the study of scleroderma antibody specificities has led to important insights into disease pathogenesis and clinical subgrouping. These advances include newly described specificities, functional antibodies and an emerging understanding of the cancer-scleroderma relationship.

PubMed Disclaimer

References

    1. Allanore Y, Simms R, Distler O, Trojanowska M, Pope J, Denton CP, & Varga J (2015). Systemic sclerosis. Nature Reviews Disease Primers, 1, 15002 10.1038/nrdp.2015.2 - DOI - PubMed
    1. Shah AA, Rosen A, Hummers L, Wigley F, & Casciola-Rosen L (2010). Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis & Rheumatism, 62(9), 2787–2795. 10.1002/art.27549 - DOI - PMC - PubMed
    1. Shah AA, Casciola-Rosen L, & Rosen A (2015). Review: cancer-induced autoimmunity in the rheumatic diseases. Arthritis & Rheumatology (Hoboken, N.J.), 67(2), 317–26. 10.1002/art.38928 - DOI - PMC - PubMed
    1. Joseph CG, Darrah E, Shah AA, Skora AD, Casciola-Rosen LA, Wigley FM, Boin F, Fava A, Thoburn C, Kinde I, Jiao Y, Papadopoulos N, Kinzler KW, Vogelstein B, Rosen A. (2014). Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 10;343(6167):152–7. doi: 10.1126/science.1246886. Epub 2013 Dec 5. - DOI - PMC - PubMed

    2. Seminal paper providing evidence that scleroderma in a subgroup of RNApol3-positive patients results from the immune system’s response to the cancer. Studying cancers in scleroderma patients, genetic alterations were discovered in the POLR3A locus of cancers in RNApol3-positive patients but not RNApol3 negative, suggesting the autoimmune disease may be initiated by exposure to foreign antigens that cross-reactive with endogenous molecules.

    1. Lazzaroni M-G, Cavazzana I, Colombo E, Dobrota R, Hernandez J, Hesselstrand R, … Airò P (2017). Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening. The Journal of Rheumatology, 44(5), 639–647. 10.3899/jrheum.160817 - DOI - PubMed

Publication types